Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-11-09
1995-09-05
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544267, 544270, 544272, 514265, C07D47306, A61K 3152
Patent
active
054479339
ABSTRACT:
A novel xanthine derivative of the formula (I): ##STR1## wherein one of R.sup.1 and R.sup.2 represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl; and the other represents
REFERENCES:
patent: 4576947 (1986-03-01), Hinze et al.
patent: 4599338 (1986-07-01), Regnier et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 5068236 (1991-11-01), Suzuki et al.
patent: 5175291 (1992-12-01), Kufner-Muhl
Patel et al. Amer. Soc. Pharmacol. and Experimental Therapeutics; Mol. Pharm 33:585-91; 1989.
J. Linden et al., ".sup.125 I-Labeled 8-Phenylxanthine Derivatives: Antagonist Radioligands for Adenosine A.sub.1 Receptors," Journal of Medicinal Chemistry, vol. 31, No. 4, Apr. 1988, pp. 745-751.
Shiozaki, et al., "Effects of KW-6055, A Novel Benzylpyridine Derivative, on Various Experimental Amnesia Models", Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, vol. 2 (1990) 449:52.
Merlos, et al., "Structure-Activity Relationships in a Series of Xanthine Derivatives", Eur. J. Med. Chem., vol. 25 (1990) 653:58.
Patel, et al., ".sup.125 I-BW-A844U, an Antagonist Radioligand with High Affinity and Selectivity for Adenosine A.sub.1 Receptors", Mol. Pharmacol., vol. 33 (1988) 585:91.
Ishii Akio
Kato Hiromasa
Shimada Jun'ichi
Shiozaki Shizuo
Suzuki Fumio
Kyowa Hakko Kogyo Co. Ltd.
Shah Mukund J.
Sripada P. K.
LandOfFree
Xanthine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Xanthine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Xanthine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-472923